The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients - Wikidata - wikimedia - TriplyDB

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

http://www.wikidata.org/entity/Q26797478

about

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.PD-1/PD-L1 blockage in cancer treatment-from basic research to clinical application.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.HIV-Associated Lung Cancer.Radiotherapy and immunotherapy: a beneficial liaison?Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.Inflammatory microenvironment in the initiation and progression of bladder cancer.Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.Role of immune microenvironment in gastrointestinal stromal tumours.The emerging role of immune checkpoint based approaches in AML and MDS.Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.

P2860

Q26740288-3B08F5BF-3EA5-4E14-A7A8-4A88694197DC Q27853353-47295F62-3A7A-49DF-8B19-7B2542168684 Q28076071-C000FDF3-0B08-43F8-A6B3-44AEE9D7BE33 Q28076294-F3337087-1AE0-44AE-8B4A-DCE16905A5A9 Q37303319-761918BC-32AB-4084-A4D6-8094F500BFA0 Q37322466-F866EAB8-0D7F-4C7A-ABB2-68C771C2D311 Q37327597-AC50F7EB-D809-4541-8445-268564F6BF2D Q37564425-2EC596FD-CAAB-4F20-8121-7AA9FF7F0707 Q37662169-2D40F28F-5FE7-4D71-841F-C127805C199D Q37725613-E7563973-30A6-46B8-83B8-5C59A908F8C1 Q38770455-48E97F6B-BEAC-4C39-B0EF-F4A205845580 Q38770458-10EB582D-677F-4D54-BCB2-C263CA41D7D2 Q38929261-EAC352A2-B72B-4F6E-9C45-DB3FF9227E52 Q39017268-216E969F-48A9-4BA2-8AB3-513C879EDB78 Q39193035-113517B3-16A0-4FFA-A7FA-2E55541E727C Q40117779-34D885F3-6003-4384-B9F2-F986B7CF1B81 Q41221347-E1EB50C2-6A0D-4F99-9D0E-D88C41972EC8 Q41709168-297A2D47-B3B5-4BF7-97A6-6F64E7553C3D Q46779353-47FBD74E-3945-4218-8700-647EB819912C Q47112946-BB9552E1-6949-4074-9667-5E31293EFF7B Q47856440-D1018C07-94A1-46B8-9EEE-A6D5C87F6460 Q48173100-8020DE71-B54B-4ACA-8B16-763B618636CD Q55263819-FA512005-52BD-43AC-B5C4-B5486C925241

P2860

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

http://www.wikidata.org/entity/Q26797478

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The anticancer immune response ...... antibodies in cancer patients

@ast

The anticancer immune response ...... antibodies in cancer patients

@en

The anticancer immune response ...... antibodies in cancer patients

@nl

type

label

The anticancer immune response ...... antibodies in cancer patients

@ast

The anticancer immune response ...... antibodies in cancer patients

@en

The anticancer immune response ...... antibodies in cancer patients

@nl

prefLabel

The anticancer immune response ...... antibodies in cancer patients

@ast

The anticancer immune response ...... antibodies in cancer patients

@en

The anticancer immune response ...... antibodies in cancer patients

@nl

P1433

Q26797478-A4ACFCC3-E9F0-4CE8-BD0C-75DF753B94CE

P1476

Q26797478-7D0228E1-111E-4A29-B3FD-80BB0281059F

P2093

Q26797478-2A98BB2F-6F1F-46D3-B2AA-D609D39FFBC8

Q26797478-3A552051-F809-4CA2-9A0C-566AA46BF9AF

Q26797478-442A1B59-82E2-4541-BBD0-DCCC2A33FF78

Q26797478-469CC9E2-7970-4C96-B313-6E99CE4303D9

Q26797478-48D5DC12-0E6B-4371-8011-EF5D2A45039A

Q26797478-767D06B8-5F07-4BF3-9B59-BC79369D67E8

Q26797478-98EEC834-B07D-4781-9864-3A6590B80358

Q26797478-D12FA111-EF0D-4C6B-8BA7-D79734E2A395

P275

Q26797478-945AF7E3-E472-44B8-A25D-61F0AC2EB834

P2860

Q26797478-008716E6-919F-436C-A7BB-62E2ED6E5F4D

Q26797478-071ABFD1-2368-4C34-B8F1-ADC234699241

Q26797478-075058D9-36EE-4617-B123-CA3D46A8B3D6

Q26797478-0B88762F-3553-4354-B6C0-BAF1E31E9BAF

Q26797478-0C072D01-FC1E-491C-B4C2-489B26095C9C

Q26797478-0C29D934-8DAD-4524-ACD3-2B32942486F7

Q26797478-0E368CB5-5D89-449F-94B3-D8C9A6F8C26B

Q26797478-0ECA3138-344C-430D-A897-02E4CE76DB40

Q26797478-102F6629-4FAE-4F0E-828E-81F8FD4C342E

Q26797478-10504E2E-C3B7-4675-B3F3-5CA0B28A1E23

P304

Q26797478-58A1BC47-959C-4D37-8BAC-7417D17AA144

P31

Q26797478-0A7ECADE-645B-47D0-9EF7-3905AB18BB90

Q26797478-91F82CDA-783F-45BE-A1B6-B397E871FFFD

P3181

Q26797478-EA0BE121-32FF-427A-9A60-284041F58711

P356

Q26797478-11F96470-6703-4A53-A50A-36BC25ED7857

P407

Q26797478-A9BFBFF8-FADA-42E6-94F3-48EA210C200F

P433

Q26797478-73868DCE-2B23-4E70-B370-371D73768019

P478

Q26797478-8DF66473-B5F8-449D-9A29-8E7FC4529FE5

P5008

Q26797478-4B0ED46D-E1F9-41D4-910E-61A5C0B37989

P577

Q26797478-28F02A20-C201-4D5A-A2C3-F5308FB2A218

P5875

Q26797478-FC9F39B1-2D4B-434C-ABA6-A451E4B84548

P698

Q26797478-00409A97-3A8F-4839-8491-9A9C255B94F2

P921

Q26797478-46C44E08-A39E-4654-ABB3-3ADE0C100018

Q26797478-513CE7B4-D9C1-4451-95F6-D740105CD5C0

Q26797478-702C8588-04AE-42DE-A415-803074A7350B

Q26797478-7AA0C9CA-9304-4C17-A377-0A7CEE2BFFE9

Q26797478-93BDA389-9A9A-4553-A69C-BD5BFC92B9CD

Q26797478-A0AD6EA1-B44C-4EE0-A177-A3E89BA0D7CD

Q26797478-B7F1EADD-1C37-4E42-B94C-6A665BB8649F

Q26797478-C2A547A6-F4D4-4908-BA64-499005D7EE58

P932

Q26797478-B932F920-B36D-4B10-BB7E-A8B44474B347

P3181

P356

ONCOTARGET.5107

P1433

P1476

The anticancer immune response ...... antibodies in cancer patients

@en

P2093

Da Li

http://www.w3.org/2001/XMLSchema#string

Hongming Pan

http://www.w3.org/2001/XMLSchema#string

Junhong Ma

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Weidong Han

http://www.w3.org/2001/XMLSchema#string

Xian Wang

http://www.w3.org/2001/XMLSchema#string

Xinbing Sui

http://www.w3.org/2001/XMLSchema#string

Yong Fang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

PD-1 and its ligands in tolerance and immunity

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

P304

19393-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3214540

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.5107

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281311546

http://www.w3.org/2001/XMLSchema#string

P698

26305724

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

monoclonal antibody

membrane proteins

P932

4637293

http://www.w3.org/2001/XMLSchema#string